Clinical Trial Update: Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the efficacy of bimatoprost 0.03% in glaucoma patients who were low responders to latanoprost. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• Bimatoprost 0.03% (bimatoprost)

Snippet

Sponsor: Innovative Medical | Conditions: Glaucoma | Phase 4 | Status: COMPLETED